Skip to main content
SpringerLink
Log in

Drug Utilisation Studies as Tools in Health Economics

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

Drug utilisation and many pharmacoeconomic studies use pharmacoepidemiological methods characterised by the study of drugs from a socioeconomic perspective. Drug utilisation studies may be defined as studies of the marketing, distribution, prescription and use of drugs in a society, with special emphasis on the resulting medical, social and economic consequences. Pharmacoeconomic studies are used to measure drug efficiency, through comparison of the costs and effects of alternative therapies.

Drug utilisation studies can provide highly valuable information, at a reasonable price, on the costs and effects (harmful and beneficial) of drugs. Such studies make available much useful information including indirect data on morbidity, the pharmaceutical component of the treatment cost of an illness, therapeutic compliance, the incidence of adverse reactions, the effectiveness of drug consumption and the choice of comparators. This information can k of great use in the subsequent elaboration of phamacoeconomic studies, or in the selection of problematic areas in which these studies may be applied.

Pharmacoeconomic studies, in turn, can be used to discover the economic repercussions of inappropriate prescribing and to quantify the cost effectiveness of various therapeutic interventions.

The use of drug utilisation studies in conjunction with pharmacoeconornic analysis can result in more cost effective utilisation of medicines and a better utilisation of pharmacoeconomic methods, both of which contribute to a more rational use of drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agenäs I, Andrew M. Sales statistics. In Nordic Statistics on Medicines 1981-1983: 1, NLN Publication number 13, Nordic Council on Medicines, Uppsala, 1983

    Google Scholar 

  • Avorn J, Soumerai SB. Improving drug-therapy decision through educational outreach: a randomized controlled trial of academically based ‘detailing’. New England Journal of Medicine 308: 1457–1463, 1983

    Article  PubMed  CAS  Google Scholar 

  • Baksaas I. Patterns in drug utilization: national and international aspects - antihypertensive drugs. Acta Medica Scandinavica 683: 59–66, 1984

    PubMed  CAS  Google Scholar 

  • Baksaas I, Ltinde PKM. Drug utilization: pharmacokinetics in the community. Trends in Pharmacological Sciences 2: 5–7, 1981

    Google Scholar 

  • Bergman U, Boman G, Wiholm BE. Epidemiology of adverse reactions to phenformin and metformin. British Medical journal 2: 464–466, 1978

    Article  PubMed  CAS  Google Scholar 

  • Bergman U, Elmes P, Halse M, et al. The measurement of drug consumption: drugs for diabetes in Northern Ireland. Norway and Sweden. European Journal of Clinical Pharmacology 8: 33–89, 1975

    Article  Google Scholar 

  • Bergman U, Sjöqvist F. Measurement of drug utilization in Sweden: methodological and clinical implications. Acta Medica Scandinavica 683: 15–22, 1984

    PubMed  CAS  Google Scholar 

  • Bergman U, Wessling A, Sjöqvist F. Validation of observed differences in the utilization of antihypertensive drugs and antidiabetic drugs in Northern Ireland, Norway, and Sweden. European Journal of Clinical Pharmacology 29: 1–8, 1985

    Article  PubMed  Google Scholar 

  • Blackburn JL. Impact of drug usage review on drug utilisation. Pharmacoeconomics 3: 14–21, 1993

    Article  PubMed  CAS  Google Scholar 

  • Boethius G. Approaches to assessing the rationality of drug usage in a developed country. Acta Medica Scandinavica 721: 21–26, 1988

    PubMed  CAS  Google Scholar 

  • Bootman JL, Larson UN, McGhan WF, Townsend RJ. Pharmacoeconomic research and dinical trials. DICP: Annals of Pharmacotherapy 23: 693–697, 1989

    PubMed  CAS  Google Scholar 

  • Bootman JL, Townsend RJ, McGhan Wf. Principles of pharmacoeconomics, pp. 3–17, Harvey Whitney, Cincinnati, 1991

    Google Scholar 

  • Brenner G. Methods to assess health economic aspects on drug utilization. Acta Medica Scandinavica 721: 31–35, 1988

    PubMed  CAS  Google Scholar 

  • Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiological studies: strengths and limitations. Journal of Clinical Epidemiology 42: 937–945, 1989

    Article  PubMed  CAS  Google Scholar 

  • Brodie DC. Drug utilization review/planning. Hospitals 46: 103–112, 1972

    PubMed  CAS  Google Scholar 

  • Brodie DC, Smith WE. Constructing a conceptual model of drug utilization review. Hospitals 50: 143–150, 1976

    PubMed  CAS  Google Scholar 

  • Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis, Department of Health and Community Services, Canberra, 1990

  • Denig P, Haaijer-Ruskamp FM, Zijsling DH. Impact of a drug bulletin on the knowledge, perception of drug utility, and prescribing behavior of physicians. DICP: Annals of Pharmacotherapy 24: 87–93, 1990

    PubMed  CAS  Google Scholar 

  • Drummond M. Cost-of-illness studies: A major headache? PharmacoEconomics 2: 1–4, 1992

    Article  PubMed  CAS  Google Scholar 

  • Drummond M, Smith GT, Wells N. Economic evaluation in the development of medicines, pp. 28–29, Office of Health Economics, London, 1988

    Google Scholar 

  • Edlavitch SA. Postmarketing surveillance methodologies. Drug intelligence and Clinical Pharmacy 22: 68–78, 1988

    PubMed  CAS  Google Scholar 

  • Eisenbcrg JM. Clinical economics: a guide to the economic analysis of clinical practices. Journal of the American Medical Association 262: 2879–2886, 1989

    Article  Google Scholar 

  • Erwin WG. The definition of drug utilization review: statement of issues. Clinical Pharmacology and Therapeutics 50: 596–599, 1991

    Article  PubMed  CAS  Google Scholar 

  • Erill S. Clinical pharmacology in Spain. Clinical Pharmacology and Therapeutics 16: 597–604, 1974

    PubMed  CAS  Google Scholar 

  • Feinstein AR. Para-analysis, faute de mieux. and the perils of riding on a data barge. Journal of Clinical Epidemiology 42: 929–935, 1989

    Article  PubMed  CAS  Google Scholar 

  • Fendler KJ, Gumbhir AK, Sail K. The impact of drug bulletins on physician prescribing habits in a health maintenance organization. Drug Intelligence and Clinical Pharmacy 18: 627–631, 1984

    PubMed  CAS  Google Scholar 

  • Fish CA, Kirking DM, Martin JB. Information systems for evaluating the quality of prescribing. DICP: Annals of Pharmacotherapy 26: 392–398, 1992

    CAS  Google Scholar 

  • Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1: 20–31, 1992

    Article  PubMed  CAS  Google Scholar 

  • Garratini S, Tognoni G. Drug utilisation review and pharmacoeconomics: interaction after parallel development? PharmacoEconomics 4: 162–172, 1993

    Article  Google Scholar 

  • Gross FH. Drug utilization data in risk/benefit analyses of drugs: benefit analysis. Acta Medica Scandinavica 683: 141–147, 1984

    PubMed  CAS  Google Scholar 

  • Guyatt G, Drurmmond M, Fenny D, Tugwell P, Stoddait G, et al. Guidelines for the clinical and economic evaluation of health care technologies. Social Science and Medicine 22: 393–408, 1986

    Article  PubMed  CAS  Google Scholar 

  • Hemminki E. Review of literature on the factors affecting drug prescribing. Social Science and Medicine 9: 111–115, 1975

    Article  CAS  Google Scholar 

  • Henry D. Economic analysis as an aid to subsidisation: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1: 54–67, 1992

    Article  PubMed  CAS  Google Scholar 

  • Hjort P, Holmen J, Waaler HT. Relation between drug utilization and morbidity pattern: antihypertensive drugs. Acta Medica Scandinavica 683: 89–93, 1984

    PubMed  CAS  Google Scholar 

  • Hull FM, Westerman RF, Jonkers R. Comparison of prescribing habits of general practitioners in The Netherlands versus England and Wales. Pharmacoeconomics 2: 77–86, 1992

    Article  PubMed  CAS  Google Scholar 

  • Inman WHW. Prescription-event monitoring: a preliminal study of benoxaprofen and fenbufen. Acta Medica Scandinavica 683: 119–126, 1984

    PubMed  CAS  Google Scholar 

  • Ioannides-Demos LL, Eckert GM, McLean AJ. Pharmacoeconomic consequences of measurement and modification of hospital drug use. Pharmacoeconomics 2: 15–33, 1992

    Article  PubMed  CAS  Google Scholar 

  • Jakovljevic V, Slanulovic M. Extremes in drug utilization patterns. Acta Medica Scandinavica 683: 67–69, 1984

    PubMed  CAS  Google Scholar 

  • Jones K, Van der Carr SW, Rosa F, Morse L, LeRoy A. Medicaid drug-event data: an emerging tool for evaluation of drug risk. Acta Medica Scandinavica 683: 127–134, 1984

    PubMed  CAS  Google Scholar 

  • Knapp DA. Development of criteria for drug utilization review. Clin Pharmacology and Therapeutics 50: 600–602, 1991

    Article  CAS  Google Scholar 

  • Kotzan L, Carroll NV, Kotzan JA. Influence of age, sex, and race om prescription drug use among Georgia Medicaid recipients. American Journal of Hospital Pharmacy 46: 287–290, 1989

    PubMed  CAS  Google Scholar 

  • Kreling DH, Mott DA. The cost effectiveness of drug utilisation review in an outpatient setting. PharmacoEconomics 4: 414–436, 1993

    Article  PubMed  CAS  Google Scholar 

  • Laporte JR, Porta M, Capella. Drug utilization studies: a tool for determining the effectiveness of drug use. British Journal of Clinical Pharmacology 16: 301–304, 1983

    Article  PubMed  CAS  Google Scholar 

  • Lasagna L. A plea for the ‘naturalistic’ study of medicines. European Journal of Clinical Pharmacology 7: 153–154, 1974

    Article  PubMed  CAS  Google Scholar 

  • Lasagna L. Are drug benefits also part of pharmacoepidemiology? Journal of Clinical Epidemiology 43: 849–850, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lee D, Bergman U. Studies of drug utilization. In Strom (Ed.) Pharmacoepidemiology, pp. 259–274, Churchill Livingstone, New York, 1989

    Google Scholar 

  • Lewis NJW, Patwell JT, Briesacher BA. The role of insurance claim databases in drug therapy outcomes research. PharmacoEconomics 4: 323–330, 1992

    Article  CAS  Google Scholar 

  • Liljestrand A. Drug utilization data in benefit analysis of drugs. Acta Medica Scandinavica 683: 135–139, 1984

    PubMed  CAS  Google Scholar 

  • Lunde PKM.Baksaas I. Epidemiology of drug utilization: basic concepts and methodology. Acta Medica Scandinavica 721: 7–11, 1988

    PubMed  CAS  Google Scholar 

  • Lunde PKM, Baksaas I, Halvorsen T, Strømnes B, Oydin K. The methodology of drug utilization studies. In Bergman et al. (Eds) Studies in drug utilization, Vol. 8, pp. 17–28, WHO Regional Publications: European Series, Copenhagen, 1979

    Google Scholar 

  • Maling TJB, Kawachi I. Minimum effective dosage in the drug treatment of hypertension: a cost effective strategy for prescribers. New Zealand Medical Journal 103: 231–233, 1990

    PubMed  CAS  Google Scholar 

  • Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 22: 719–748, 1959

    PubMed  CAS  Google Scholar 

  • Morse ML, Leroy AA, Gaylord TA, Kellengberger T. Reducing drug therapy-induced hospitalization: impact of drug utilization review. Drug Information Journal, October-December: 119, 1982

  • Raisch DW. A model of methods for influencing prescribing: Part I. A review of prescribing models, persuasion theories, and administrative and educational methods. DICP: Annals of Pharmacotherapy 24: 417–421, 1990

    PubMed  CAS  Google Scholar 

  • Rucker TD. Data, sources, and limitations. Journal of the American Medical Association 230: 888–890, 1974

    Article  PubMed  CAS  Google Scholar 

  • Sacristan JA, Soto J, Galende I. Evaluation of pharmacoeconomic studies: utilisation of a checklist. Annals of Pharmacotherapy 27: 1126–1133, 1993

    PubMed  CAS  Google Scholar 

  • Serradell J, Bjomson DC, Hartzema AG. Drug utilization study methodologies: national and international perspectives. DICP: Annals of Pharmacotherapy 21: 994–1001, 1987

    CAS  Google Scholar 

  • Skegg DCG. Relation between drug utilization and morbidity. Acta Medica Scandinavica 683: 81–87, 1984

    PubMed  CAS  Google Scholar 

  • Slone D, Shapiro S, Miettinen OS, Finkle WD, Slolley PD. Drug evaluation after marketing. Annals of Internal Medicine 90: 257–261, 1979

    PubMed  CAS  Google Scholar 

  • Soumerai SB. Improving the quality and economy of in-hospital prescribing: getting more for less. Medical Journal of Australia 149: 574–576, 1988

    PubMed  CAS  Google Scholar 

  • Soumerai SB, Avorn J. Economic and policy analysis of university-based drug ‘detailing’. Medical Care 24: 313–331, 1986

    Article  PubMed  CAS  Google Scholar 

  • Steele MA, Bess DT, Franse VL, Graber SE. Cost effectiveness of two interventions for reducing outpatients prescribing costs. DICP: Annals of Pharmacotherapy 23: 497–500, 1989

    PubMed  CAS  Google Scholar 

  • Stolar MH. Drug use review: operational definitions. American Journal of Hospital Pharmacy 35: 76–78, 1978

    PubMed  CAS  Google Scholar 

  • Stole D, Shapiro S, Miettinen OS, Finkle WD, Stolley PD. Drug evaluation after marketing. Annals of Internal Medicine 90: 257–261, 1979

    Google Scholar 

  • Stolley PD. The use of vital and morbidity statistics for the detection of adverse drug reactions and for monitoring of drug safety. Journal of Clinical Pharmacology 22: 499–504, 1982

    PubMed  CAS  Google Scholar 

  • Strom BL. What is pharmacoepidemiology? In Strom (Ed.) Pharmacoepidemiology, pp. 3–12, Churchill Livingstone, New York, 1989

  • Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiologic Reviews 12: 87–107, 1990

    PubMed  CAS  Google Scholar 

  • Strom BL, Carson JL, Morse ML. The computerized on-line Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance. Clinical Pharmacology and Therapeutics 38: 359–364, 1985

    Article  PubMed  CAS  Google Scholar 

  • Strom BL, Morse ML. Use of computerized databases to survey drug utilization in relation to diagnoses. Acta Medica Scandinavica 721: 13–20, 1988

    PubMed  CAS  Google Scholar 

  • Smith M. Medication, quality of life and compliance: the role of the pharmacist. PharmacoEconomics 4: 225–230, 1992

    Article  Google Scholar 

  • Spitzer WO. Drugs as determinants of health and disease in the population: an orientation to the bridge science of pharmacoepidemiology. Journal of Clinical Epidemiology 44: 823–830, 1991

    Article  PubMed  CAS  Google Scholar 

  • Stika L. Patterns in drug utilization: national and international aspects - antidiabetic drugs. Acta Medica Scandinavica 683: 53–57, 1984

    PubMed  CAS  Google Scholar 

  • Thomson MS, Fortess EE. Cost-effectiveness analysis in health program evaluation. Evaluation Review 4: 549–568, 1980

    Article  Google Scholar 

  • Townsend JR. Postmarketing drug research and development. DICP: Annals of Pharmacotherapy 21: 134–136, 1987

    CAS  Google Scholar 

  • Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Information Journal 22: 363–378, 1988

    Google Scholar 

  • van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme PVM, et al. The introduction of computer-based patient records in The Netherlands. Annals of Internal Medicine 119: 1036–1041, 1993

    PubMed  Google Scholar 

  • Vestal RE, Guess H, Lipton H, Luscombe F, Oster G, et al. Panel IV: evaluation. The value and cost-effectiveness of drug utilization review programs. Clinical Pharmacology and Therapeutics 50: 636–638, 1991

    Article  Google Scholar 

  • Walley T, Edwards RT. Health economics in primary care in the UK. Containment of drug costs. PharmacoEconomics 3: 100–106, 1993

    Article  PubMed  CAS  Google Scholar 

  • Wessling A, Boethius G. Measures of drug use in a defined population: evaluation of the Defined Daily Dose (DDD) methodology. European Journal of Clinical Pharmacology 39: 207–210, 1990

    Article  PubMed  CAS  Google Scholar 

  • Westerholm B. Drug utilization studies: a valuable tool for the optimization of drug therapy and drug control. Journal of Social and Administrative Pharmacy 1: 1–8, 1983

    Google Scholar 

  • Westerholm B, Agenas I, Dahlstrom M, Nordenstam I. Relation between drug utilization and morbidity patterns. Acta Medica Scandinavica 683: 95–97, 1984

    PubMed  CAS  Google Scholar 

  • WHO Expert Committee. The selection of essential drugs. Report of a WHO Expert Committee World Health Organization Technical Report Series 615: 1–36, 1977

  • Wiholm BE, Westerholm B. Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. Acta Medica Scandinavica 683: 107–117, 1984

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Health Economics Department and Clinical Research Department, Lilly S.A., Avenida de la Industria, 30, 28100-Alcobendas, Madrid, Spain

    José A. Sacristén

  2. Pharmacoepiderniology Department, Abbott Laboratories, Madrid, Spain

    Javier Soto

Authors
  1. José A. Sacristén
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Soto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sacristén, J., Soto, J. Drug Utilisation Studies as Tools in Health Economics. Pharmacoeconomics 5, 299–312 (1994). https://doi.org/10.2165/00019053-199405040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199405040-00005

Keywords

Search

Navigation